TY - JOUR
T1 - A new regimen of amsacrine with high-dose cytarabine is safe and effective therapy for acute leukemia
AU - Arlin, Z. A.
AU - Ahmed, T.
AU - Mittelman, A.
AU - Feldman, E.
AU - Mehta, R.
AU - Weinstein, P.
AU - Rieber, E.
AU - Sullivan, P.
AU - Baskind, P.
PY - 1987
Y1 - 1987
N2 - Amsacrine and high-dose cytarabine (HiDAc), when administered as single agents, are effective treatment of acute leukemia. When used in combination, a high remission rate is also possible. We treated 47 patients with acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and blastic phase of chronic myelogenous leukemia (CML) with a combination of amsacrine and HiDAc. The patients received amsacrine 200 mg/m2 daily for three days and, concurrently, HiDAc 3 g/m2 over three hours once daily for five days. Of 20 evaluable patients with AML in relapse, there were 12 remissions; of seven additional patients with primary refractory AML, there were two remissions, and of 12 patients with ALL in relapse, there were eight remissions. The three patients with blastic phase CML and the three patients with biphenotypic leukemia did not respond. Nausea, vomiting, stomatitis, hepatic dysfunction, and diarrhea were common, but cutaneous, conjunctival, and significant cerebellar side effects were absent. We conclude that this regimen is highly effective therapy for AML and ALL and is also safe, eliminating the major toxicities encountered with HiDAc.
AB - Amsacrine and high-dose cytarabine (HiDAc), when administered as single agents, are effective treatment of acute leukemia. When used in combination, a high remission rate is also possible. We treated 47 patients with acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and blastic phase of chronic myelogenous leukemia (CML) with a combination of amsacrine and HiDAc. The patients received amsacrine 200 mg/m2 daily for three days and, concurrently, HiDAc 3 g/m2 over three hours once daily for five days. Of 20 evaluable patients with AML in relapse, there were 12 remissions; of seven additional patients with primary refractory AML, there were two remissions, and of 12 patients with ALL in relapse, there were eight remissions. The three patients with blastic phase CML and the three patients with biphenotypic leukemia did not respond. Nausea, vomiting, stomatitis, hepatic dysfunction, and diarrhea were common, but cutaneous, conjunctival, and significant cerebellar side effects were absent. We conclude that this regimen is highly effective therapy for AML and ALL and is also safe, eliminating the major toxicities encountered with HiDAc.
UR - http://www.scopus.com/inward/record.url?scp=0023098432&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023098432&partnerID=8YFLogxK
U2 - 10.1200/JCO.1987.5.3.371
DO - 10.1200/JCO.1987.5.3.371
M3 - Article
AN - SCOPUS:0023098432
SN - 0732-183X
VL - 5
SP - 371
EP - 375
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 3
ER -